Donna Guralski

Title: Donna Guralski: Innovator in Diabetes Research

Introduction

Donna Guralski is a prominent inventor based in Oxford, CT (US). She has made significant contributions to the field of diabetes research through her innovative work on aminopeptidases. With a total of 2 patents, her inventions focus on improving the understanding and treatment of insulin resistance.

Latest Patents

Guralski's latest patents include the development of a glucose transporter vesicle aminopeptidase. This aminopeptidase is a crucial component of GLUT4-containing vesicles in their natural state and plays a role in cleaving insulin. The claimed protein has an apparent molecular weight of approximately 110 kD in its deglycosylated form, with a predicted molecular weight of 117,239 Daltons. The patent details specific amino acid sequences, including Phe-Ala-Ala-Thr-Gln-Phe-Glu-Pro-Leu-Ala-Ala (SEQ ID NO: 1) and Ile-Leu-Gln-Asn-Gln-Ile-Gln-Gln-Gln-Thr-Arg-Thr-Asp-Glu-Gly-Xaa-Pro-Xaa-Met (SEQ ID NO: 2). Additionally, it describes modulators of the aminopeptidase's activity and methods for treating syndromes of insulin resistance, including diabetes.

Career Highlights

Guralski is currently associated with Bayer Corporation, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of insulin resistance and potential therapeutic approaches.

Collaborations

Some of her notable coworkers include William J. Knowles and John T. Letsinger, who have collaborated with her on various projects related to her patents.

Conclusion

Donna Guralski's innovative contributions to diabetes research through her patents highlight her role as a key inventor in the field. Her work continues to pave the way for advancements in the treatment of insulin resistance and diabetes.